inoperableness or metastatic breast cancer
Conditions
Interventions
Treatment with trastuzumab (8mg/kg followed by 6mg/kg, q3w, or 4mg/kg followed by 2mg/kg weekly) and eribulin (on day 1 and 8 every 3 weeks). Continue to disease progression.
Sponsors
Wakayama Medical University Department of Thoracic and Cardiovascular Surgery
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1)With serious drug allergy (2) Systemic infection (3)Control of pleural effusion,ascites and pericardial fluid (4)Clinical symptoms with brain metastasis (5) Severe complications 1) Control of bad heart disease 2) Myocardial infarction within 6 months 3) Cirrhosis 4) Between interstitial Pneumonitis and pulmonary fibrosis 5) Bleeding tendency (6) Active cancer (7) Pregnancy, breast feeding or wish of future bearing (8) Long-term corticosteroid therapy (9) Wide range of radiation therapy (10)Refusal of blood transfusion (11) Patients considered inappropriate by the study investigator
Exclusion criteria
Exclusion criteria: (1)With serious drug allergy (2) Systemic infection (3) Control of pleural effusion, ascites and pericardial fluid (4)Clinical symptoms with brain metastasis (5) Severe complications 1) Control of bad heart disease 2) Myocardial infarction within 6 months 3) Cirrhosis 4) Between interstitial Pneumonitis and pulmonary fibrosis 5) Bleeding tendency (6) Active cancer (7) Pregnancy, breast feeding or wish of future bearing (8) Long-term corticosteroid therapy (9) Wide range of radiation therapy (10)Refusal of blood transfusion (11) Patients considered inappropriate by the study investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to Treatment Failure Progression-Free Survival Overall Survival Adverse event | — |
Countries
Japan
Contacts
Public ContactShoji Oura
Wakayama Medical University Department of Thoracic and Cardiovascular Surgery
Outcome results
None listed